Table Graph
      published meta-analysis   sensitivity analysis   studies

control in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 4.98 [0.58; 42.68] 4.98[0.58; 42.68]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%11,636NAnot evaluable symptomatic Covid-19detailed resultsAstraZeneca phase 3 US (D8110C00001), 2021 0.24 [0.18; 0.32] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 3.00 [2.35; 3.84] 0.85[0.07; 10.11]AstraZeneca phase 3 US (D8110C00001), 2021, ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)299%17,177lownot evaluable asymptomatic COVID casedetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 3.04 [2.10; 4.41] 3.04[2.10; 4.41]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%11,636NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 2.26 [1.70; 3.00] 2.26[1.70; 3.00]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%11,636NAnot evaluable severe COVID-19 occurrencedetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 2.05 [0.07; 61.14] 2.05[0.07; 61.14]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%23,745NAnot evaluable vaccine efficacy after dose 1 (and before dose 2)detailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 4.17 [2.43; 7.13] 4.17[2.43; 7.13]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%18,494NAnot evaluable serious adverse eventsdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1.16 [0.85; 1.57] 1.16[0.85; 1.57]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%23,745NAnot evaluable adverse eventsdetailed resultsAsano, 2022 1.44 [0.71; 2.93] AstraZeneca phase 3 US (D8110C00001), 2021 1.62 [1.54; 1.71] 1.62[1.54; 1.70]Asano, 2022, AstraZeneca phase 3 US (D8110C00001), 202120%32,635NAnot evaluable ATE (Myocardial infarction or ischemic stroke)detailed resultsAstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV) 2.26 [0.78; 6.51] AstraZeneca phase 3 US (D8110C00001), 2021 0.12 [0.01; 2.77] 0.78[0.05; 12.02]AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV), AstraZeneca phase 3 US (D8110C00001), 2021267%56,623NAnot evaluable Guillain-Barré syndrome detailed resultsAstraZeneca phase 3 US (D8110C00001), 2021 1.00 [0.03; 29.81] 1.00[0.03; 29.81]AstraZeneca phase 3 US (D8110C00001), 202110%32,379NAnot evaluable intracranial hemorrhage detailed resultsAsano, 2022 0.33 [0.01; 16.88] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV) 4.11 [0.19; 91.10] AstraZeneca phase 3 US (D8110C00001), 2021 0.50 [0.01; 25.21] 1.14[0.14; 9.01]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV), AstraZeneca phase 3 US (D8110C00001), 202130%56,879NAnot evaluable ischemic strokedetailed resultsAsano, 2022 0.33 [0.01; 16.88] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV) 3.08 [0.32; 29.62] AstraZeneca phase 3 US (D8110C00001), 2021 0.13 [0.01; 2.77] 0.69[0.09; 5.55]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV), AstraZeneca phase 3 US (D8110C00001), 2021332%56,879NAnot evaluable Myocardial infarction detailed resultsAsano, 2022 0.33 [0.01; 16.88] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV) 4.11 [0.46; 36.76] AstraZeneca phase 3 US (D8110C00001), 2021 0.25 [0.01; 7.46] 1.16[0.17; 7.77]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV), AstraZeneca phase 3 US (D8110C00001), 2021318%56,879NAnot evaluable pulmonary embolismdetailed resultsAsano, 2022 0.33 [0.01; 16.88] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV) 2.05 [0.07; 61.22] AstraZeneca phase 3 US (D8110C00001), 2021 0.50 [0.01; 25.21] 0.78[0.09; 6.68]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV), AstraZeneca phase 3 US (D8110C00001), 202130%56,879NAnot evaluable serious adverse events (SAE), anydetailed resultsAsano, 2022 0.16 [0.01; 4.96] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV) 1.21 [0.93; 1.57] AstraZeneca phase 3 US (D8110C00001), 2021 0.95 [0.68; 1.33] 1.09[0.85; 1.39]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV), AstraZeneca phase 3 US (D8110C00001), 2021318%56,879NAnot evaluable venous thromboembolism detailed resultsAstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV) 4.11 [0.19; 91.10] 4.11[0.19; 91.10]AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 (REV)10%24,244NAnot evaluable Bell's palsydetailed resultsAstraZeneca phase 3 US (D8110C00001), 2021 1.00 [0.03; 29.81] ChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1.03 [0.21; 5.08] 1.02[0.24; 4.34]AstraZeneca phase 3 US (D8110C00001), 2021, ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)20%56,124moderatenot evaluable immediate allergic reactiondetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 0.51 [0.02; 15.28] 0.51[0.02; 15.28]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%23,745NAnot evaluable multiple sclerosisdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 0.51 [0.02; 15.28] 0.51[0.02; 15.28]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%23,745NAnot evaluable myelitisdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 0.51 [0.05; 5.65] 0.51[0.05; 5.65]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%23,745NAnot evaluable Potential Immune Gastrointestinal disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 3.08 [0.32; 29.58] 3.08[0.32; 29.58]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%23,745NAnot evaluable Potential Immune Musculoskeletal disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1.03 [0.06; 16.40] 1.03[0.06; 16.40]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%23,745NAnot evaluable Potential Immune Neuroinflammatory disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 0.82 [0.22; 3.06] 0.82[0.22; 3.06]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%23,745NAnot evaluable Potential Immune Skin disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 1.37 [0.31; 6.11] 1.37[0.31; 6.11]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%23,745NAnot evaluable Potential Immune Vasculitidesdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 2.05 [0.07; 61.14] 2.05[0.07; 61.14]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%23,745NAnot evaluable Thromboembolic eventsdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 (REV) 2.05 [0.62; 6.81] 2.05[0.62; 6.81]ChAdOx1 phase 3 (AstraZeneca), 2020 (REV)10%23,745NAnot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-06-14 05:09 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 649,650,589,651,968 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons